The Effects of Dextroamphetamine on Brain Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004556|
Recruitment Status : Completed
First Posted : February 9, 2000
Last Update Posted : September 28, 2018
The purpose of this study is to determine the effects of the drug dextroamphetamine on the brain function and mood of healthy volunteers.
Monoaminergic drugs are substances that affect the nervous system; these drugs can raise, hamper, or have no effect on brain function when given to healthy individuals. Different responses to a drug may be the result of genetic variations. This study will examine the effects of the monoaminergic drug dextroamphetamine on thought and sensorimotor processes while participants perform a variety of tasks.
Participants in this study will undergo a medical history, physical examination, blood tests, and an electrocardiogram (EKG). Women of reproductive potential will undergo a pregnancy test. Participants will be given either dextroamphetamine or placebo (an inactive solution) on two occasions separated by at least 3 to 7 days. Participants will then perform neuropsychological tests that will measure attention, problem solving, memory, and ability to complete simple motor tasks.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||108 participants|
|Official Title:||Mechanisms of Individual Variation of Dextroamphetamine Effects in Normal Human Subjects|
|Study Start Date :||September 30, 1991|
|Study Completion Date :||September 25, 2018|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004556
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Karen F Berman, M.D.||National Institute of Mental Health (NIMH)|